MALVERN, Pa., March 21, 2022 (World NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a scientific-stage biopharmaceutical corporation concentrated on identifying, establishing, and commercializing gene therapies to heal blindness disorders and establishing a vaccine to save lives from COVID-19, now declared the appointment of Jessica Crespo, CPA, as Main Accounting Officer and Senior Vice President, Finance. She assumed the job efficient March 18, 2022.
In this purpose, she will be responsible for the enhancement and execution of the Company’s economical system, as very well as all corporate finance, accounting, and inner and exterior fiscal reporting capabilities. She will serve as a member of Ocugen’s management workforce, reporting immediately to the CEO.
Ms. Crespo has far more than 20 yrs of expertise in accounting and fiscal management. She has been with Ocugen since 2019, formerly serving as Vice President, Company Controller and Treasurer. Ahead of becoming a member of the Organization, she held financial management roles inside of Aerie Pharmaceuticals, Aralez Pharmaceuticals and Cubist Pharmaceuticals wherever she was dependable for financial and technological accounting and SEC reporting, which includes the implementation of new accounting criteria and the accounting and reporting of intricate transactions. Prior to that, Ms. Crespo was a senior supervisor in Ernst & Young’s audit and assurance practice.
“Jess has been an significant member of the Ocugen team for approximately 3 decades and we are pleased to realize her valuable contributions with this expansion of her purpose. The Company has found transformational development more than the earlier 12 months, as we function to advance the therapies in our pipeline toward regulatory approval. Jess’ understanding and expertise will enable us maintain that momentum,” stated Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen.
Ms. Crespo retains a Bachelor of Science in Accounting from Boston University and is a Certified Public Accountant.
About Ocugen, Inc.
Ocugen, Inc. is a clinical-phase biopharmaceutical enterprise focused on discovering, producing, and commercializing gene therapies to get rid of blindness ailments and building a vaccine to conserve lives from COVID-19. Our breakthrough modifier gene therapy system has the likely to deal with several retinal conditions with a single drug — “one to a lot of,” and our novel biologic product prospect aims to provide greater treatment to patients with underserved diseases this sort of as wet age-connected macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-establishing Bharat Biotech’s COVAXIN™ vaccine prospect for COVID-19 in the U.S. and Canadian marketplaces. For additional information, please pay a visit to www.ocugen.com.
Cautionary Observe on Ahead-Searching Statements
This push launch contains forward-on the lookout statements within the which means of The Private Securities Litigation Reform Act of 1995, which are topic to hazards and uncertainties. We may possibly, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of upcoming situations or outcomes to detect these forward-hunting statements. Such statements are issue to numerous essential components, dangers and uncertainties that might cause real situations or benefits to differ materially from our present anticipations. These and other dangers and uncertainties are more absolutely explained in our periodic filings with the Securities and Exchange Fee (“SEC”), together with the hazard components described in the portion entitled “Risk Factors” in the quarterly and annual experiences that we file with the SEC. Any forward-on the lookout statements that we make in this press launch communicate only as of the date of this press release. Besides as necessary by regulation, we presume no obligation to update ahead-looking statements contained in this push release irrespective of whether as a final result of new details, long term events or in any other case, right after the day of this push release.
Ocugen Get hold of:
Head, Trader Relations & Communications